Leica Biosystems Enhances Cancer Diagnostics Through StatLab Acquisition

In a strategic move to further improve cancer analytics, Leica Biosystems, a subsidiary of Danaher Corporation, has successfully acquired StatLab Medical Products, a company renowned for its pre-analytical consumables and equipment. This acquisition, completed on September 28, 2026, is set to enhance the delivery of precise and timely diagnostics for cancer patients, a critical aspect in understanding the disease and developing targeted therapies.

The combination of Leica Biosystems’ digital pathology expertise and StatLab's trusted product portfolio is expected to streamline workflows in pathology laboratories, enabling them to transition from sample collection to diagnostic results with increased efficiency. According to Gustavo Perez-Fernandez, the Group Executive for Danaher’s Diagnostics Business, this alliance will empower clinicians to provide high-quality, timely diagnostic information, vital for determining personalized treatment paths for their patients.

A New Era in Precision Oncology

With this integration, Leica Biosystems aims to enhance its comprehensive anatomic pathology ecosystem. By offering an expanded range of solutions from specimen collection and preparation, advanced staining, to digital imaging and artificial intelligence-enabled diagnosis, both companies strive to optimize the histological workflow in laboratories. As laboratories face mounting case volumes and increasing complexities, this collaboration addresses the urgent need for technological advancements in cancer diagnostics.

Supporting Clinicians and Patients

The fusion of capabilities from both companies not only enhances operational efficiency but vastly improves patient care. StatLab’s strong relationships within the healthcare community are a valuable asset that, alongside Leica's global leadership in AI and digital pathology, positions them to advance precision oncology practices significantly. Each advancement in the diagnostic processes allows clinicians to deliver timely results which, in turn, put patients on the road to necessary treatment more quickly.

While the landscape of cancer treatment is constantly evolving with new therapies and technologies, Leica Biosystems remains committed to maintaining its focus on quality and service, ensuring that the legacy values of both brands are upheld throughout this transition.

About Leica Biosystems and Danaher Corporation

Leica Biosystems stands as a frontrunner in end-to-end cancer diagnostics, providing a comprehensive product range that supports every step of the pathology workflow. Their commitment to 'Advancing Cancer Diagnostics, Improving Lives' resonates in their corporate culture and operational focus.

Danaher Corporation, on the other hand, champions a unity of scientific innovation and technology to enhance global health, with its ecosystem of leading businesses solving complex medical challenges. Through their ongoing collaboration, Danaher’s mission of delivering life-changing therapies aimed at improving quality of life remains evident.

As the healthcare industry navigates through challenges such as labor shortages and the need for rapid advancements, the merger of Leica Biosystems and StatLab presents a promising solution aimed at enhancing patient outcomes through efficient, high-quality diagnostics. This strategic acquisition signifies not just a business transaction, but a collective vision to revolutionize cancer care and diagnostics in an increasingly complex healthcare environment.